Syndax is hit with a setback during the ASCO preview round as lead drug flops in mid-stage study

Syndax Pharmaceuticals shares $SNDX were hit hard after it released abstracts followed by a press release demonstrating that a combination of their HDAC entinostat plus Keytruda produced an objective response rate of only 11% in pre-treated cancer patients — with a progression-free survival rate of only 2.5 months.